Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01620489 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 279
- Enrollment target
NCT01620489: Completed Phase 3 study, sponsored by Novo Nordisk A/S.
NCT01620489 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 279 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (64% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01620489, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 279 participants
- Enrollment target
Study Summary
This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to investigate the efficacy and safety of liraglutide in subjects with type 2 diabetes and moderate renal impairment. The trial medication will be add-on to the subject's stable pre-trial OAD and/or insulin regimen.
Primary Outcome
Calculated as the estimated mean change from baseline in HbA1c (%) after 26 Weeks of treatment based on the statistical model.
Interventions
- DRUG placebo
- DRUG liraglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 279 participants |
| Start Date | 2012-06-14 |
| Est. Completion | 2013-08-20 |
| Phase | Phase 3 |
What the finished NCT01620489 record still lists
NCT01620489 is an interventional study that assigns participants to a tested intervention. The registered 279 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (64% lower).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01620489 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01620489 about?
NCT01620489 is a clinical study titled "Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment". This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to investigate the efficacy and safety of liraglutide in subjects with type 2 diabetes and moderate renal impairment. The trial medication will be add-on to the subject's stable pre-trial OAD and/or i...
What is the current status of trial NCT01620489?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 279 participants. The study started on 2012-06-14. Estimated completion is 2013-08-20.
What interventions are being tested in trial NCT01620489?
The interventions under investigation include: placebo (DRUG), liraglutide (DRUG).
Who is sponsoring clinical trial NCT01620489?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01620489's enrollment target sits among peer trials
279 1199th of 2000 higher than 801 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04783857 · 279 participants · Phase 4
Modifying Progesterone and Estradiol Levels to Prevent Postpartum Cigarette Smoking Relapse and Reduce Secondhand Smoke Exposure in Infants and Children
- NCT05407324 · 279 participants · Phase 2
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
- NCT06299748 · 279 participants
A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.
- NCT06582784 · 279 participants · NA
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI